Treatment failure in osteoporosis

Osteoporosis International

Volumn 23, Issue 12, 2012, Pages 2769-2774

  Diez Perez, A ^a   Adachi, J D ^b   Agnusdei, D ^c   Bilezikian, J P ^d   Compston, J E ^e   Cummings, S R ^f   Eastell, R ^g   Eriksen, E F ^h   Gonzalez Macias, J ⁱ   Liberman, U A ^j   Wahl, D A ^k   Seeman, E ^l   Kanis, J A ^m   Cooper, C ^n,o  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b MCMASTER UNIVERSITY   (Canada)

^c ELI LILLY AND COMPANY   (United States)

^d Columbia University ^*  (United States)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^f CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^g UNIVERSITY OF SHEFFIELD   (United Kingdom)

^h UNIVERSITY OF OSLO   (Norway)

ⁱ UNIVERSITY OF CANTABRIA   (Spain)

^j TEL AVIV UNIVERSITY   (Israel)

^k International Osteoporosis Foundation Switzerland   (Switzerland)

^l UNIVERSITY OF MELBOURNE   (Australia)

^m UNIVERSITY OF SHEFFIELD   (United Kingdom)

ⁿ UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^o UNIVERSITY OF OXFORD   (United Kingdom)

more..

Author keywords

Bone mineral density; Fractures; Markers of bone turnover; Osteoporosis; Treatment

Indexed keywords

AGENTS AFFECTING METABOLISM; ANABOLIC AGENT; ANTIRESORPTIVE AGENT; CALCIUM; DENOSUMAB; PARATHYROID HORMONE[1-34]; PROCOLLAGEN; RALOXIFENE; UNCLASSIFIED DRUG;

ARTICLE; BONE DENSITY; BONE REMODELING; CLINICAL ASSESSMENT; CLINICAL DECISION MAKING; DRUG SUBSTITUTION; EVIDENCE BASED PRACTICE; FRAGILITY FRACTURE; HUMAN; OSTEOLYSIS; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SUBSTITUTION THERAPY; TREATMENT FAILURE; TREATMENT PLANNING; TREATMENT RESPONSE;

BIOLOGICAL MARKERS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; HUMANS; OSTEOPOROSIS; OSTEOPOROTIC FRACTURES; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84872058152     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-012-2093-8     Document Type: Article

References (47)

1. Food and Drug Administration (1994) Guidelines for preclinical and clinical evaluation of agents used in the prevention or treatment of postmenopausal osteoporosis. Division of Metabolism and Endocrine Drug Products, Food and Drug Administration, Rockville, MD, 1994
2. Committee for Medicinal Products for Human Use (CHMP) (2006) Guideline on the evaluation of medicinal products in the treatment of primary osteoporosis. Ref CPMP/EWP/552/95Rev. 2. CHMP, London, Nov. 2006
3. Body JJ, Bergmann P, Boonen S et al (2010) Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club. Osteoporos Int 2:1657-1680
4. MacLean C, Newberry S, Maglione M et al (2008) Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med 148:197-213 (Pubitemid 351665507)
5. National Institute for Health and Clinical Excellence (2010) Final appraisal determination. Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women. NICE, London
6. National Institute for Health and Clinical Excellence (2010) Final appraisal determination, Alendronate, tidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. NICE, London
7. Chapurlat RD, Palermo L, Ramsay P, Cummings SR (2005) Risk of fracture among women who lose bone density during treatment with alendronate. The Fracture Intervention Trial. Osteoporos Int 16:842-848 (Pubitemid 40933602)
8. Watts NB, Geusens P, Barton IP, Felsenberg D (2005) Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMD. J Bone Miner Res 20:2097-2104 (Pubitemid 41698773)
9. Ettinger B, Black DM, Mitlak BH (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomised clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282:637-645 (Pubitemid 29384151)
10. Levis S, Quandt SA, Thompson D et al (2002) Alendronate reduces the risk of multiple symptomatic fractures: results from the fracture intervention trial. J Am Geriatr Soc 50:409-415 (Pubitemid 34229393)
11. Watts NB, Josse RG, Hamdy RC et al (2003) Risedronate prevents new vertebral fractures in postmenopausal women at high risk. J Clin Endocrinol Metab 88:542-549 (Pubitemid 36207787)
12. Barrett-Connor E, Nielson CM, Orwoll E, Bauer DC, Cauley JA (2010) Epidemiology of rib fractures in older men: osteoporotic Fractures in Men (MrOS) prospective cohort study. BMJ 340:c1069
13. van Staa TP, Leufkens HG, Cooper C (2002) Does a fracture at one site predict later fractures at other sites? A British cohort study. Osteoporos Int 13:624-629
14. Johnell O, Oden A, Caulin F, Kanis JA (2001) Acute and long term increase in fracture risk after hospitalization for vertebral fracture. Osteoporos Int 12:207-214 (Pubitemid 32288937)
15. Johnell O, Kanis JA, Oden A, Sernbo I, Redlund-Johnell I, Pettersen C, De Laet C, Jonsson B (2004) Fracture risk following an osteoporotic fracture. Osteoporos Int 15:175-179 (Pubitemid 38391531)
16. Kanis JA (1984) Treatment of osteoporotic fracture. Lancet 1:27-33 (Pubitemid 14213489)
17. Seeley DG, Browner WS, Nevitt MC, Genant HK, Scott JC, Cummings SR (1991) Which fractures are associated with low appendicular bone mass in elderly women? The Study of Osteoporotic Fractures Research Group. Ann Intern Med 115:837-842
18. Kanis JA, Oden A, Johnell O, Jonsson B, de Laet C, Dawson A (2001) The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int 12:417-427 (Pubitemid 32606468)
19. Mackey DC, Black DM, Bauer DC et al (2011) Effects of antiresorptive treatment on nonvertebral fracture outcomes. J Bone Miner Res 26:2411-2418
20. Marshall D, Johnell O, Wedel H (1996) Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. Br Med J 312:1254-1259 (Pubitemid 26147662)
21. Johnell O, Kanis JA, Oden A et al (2005) Predictive value of bone mineral density for hip and other fractures. J Bone Miner Res 20:1185-1194 (Pubitemid 40863806)
22. Cummings SR, Karpf DB, Harris F (2002) Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 112:281-289 (Pubitemid 34219441)
23. Sarkar S, Mitlak BH, Wong M, Stock JL, Black DM, Harper KD (2002) Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res 17:1-10 (Pubitemid 33150990)
24. Delmas PD, Li Z, Cooper C (2004) Relationship between changes in bone mineral density and fracture risk reduction with antiresorptive drugs: some issues with meta-analyses. J Bone Miner Res 19:33-37
25. Delmas PD, Seeman E (2004) Changes in bone mineral density explain little of the reduction in vertebral or non-vertebral fracture risk with anti-resorptive therapy. Bone 34:599-604 (Pubitemid 38393794)
26. CRCPD's Task Force on Bone Densitometry (2006) Technical White Paper: Bone Densitometry. October 2006. http://crcpd.org/Pubs/ BoneDensitometryWhitePaper.pdf
27. El-Hajj Fulehian G, Testa MA, Angell JA, Porrino N, Leboff MS (1995) Reproducibility of DXA absorptiometry: a model for bone loss estimates. J Bone Miner Res 10:1004-1014
28. Lodder MC, Lems WF, Ader HJ et al (2004) Reproducibility of bone mineral density measurement in daily practice. Ann Rheum Dis 63:285-289 (Pubitemid 38250672)
29. El Maghraoui A, Do Santos Zounon AA, Jroundi I et al (2005) Reproducibility of bone mineral density measurements using dual X-ray absorptiometry in daily clinical practice. Osteoporos Int 16:1742-1748 (Pubitemid 41790884)
30. Bell KJL, Hayen A, Macaskill P et al (2009) Value of routine monitoring of bone mineral density after starting bisphosphonate treatment: secondary analysis of trial data. BMJ 338:b2266
31. Cummings SR, Lui LY, Vittinghoff E et al (2010) The value of monitoring hip BMD during treatment with denosumab: one year changes in BMD and reductions in fracture risk. J Bone Miner Res 25:S1-S9
32. Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD (2003) Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 18:1051-1056 (Pubitemid 37294942)
33. Eastell R, Hannon RA, Garnero P, Campbell MJ, Delmas PD (2007) Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate: review of statistical analysis. J Bone Miner Res 22:1656-1660 (Pubitemid 351235131)
34. Reginster J-Y, Sarkar S, Zegels B et al (2004) Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk. Bone 34:344-351 (Pubitemid 38177616)
35. Sarkar S, Reginster J-Y, Crans GG, Diez-Perez A, Pinette KV, Delmas PD (2004) Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk. J Bone Miner Res 19:394-401 (Pubitemid 38787394)
36. Bauer DC, Black DM, Garnero P et al (2004) Change in bone turnover and hip, non-spine, and vertebral fracture in alendronatetreated women: the fracture intervention trial. J Bone Miner Res 19:1250-1258 (Pubitemid 41094365)
37. Delmas PD, Munoz F, Black DM et al (2009) Effects of yearly zoledronic acid 5 mg on bone turnover markers and relation of PINP with fracture reduction in postmenopausal women with osteoporosis. J Bone Miner Res 24:1544-1551
38. Glover SJ, Gall M, Schoenborn-Kellenberger O et al (2009) Establishing a reference interval for bone turnover markers in 637 healthy, young, premenopausal women from the United Kingdom, France, Belgium, and the United States. J Bone Miner Res 24:389-397
39. Vasikaran S, Eastell R, Bruyere O, for the IOF-IFCC Bone Marker Standards Working Group et al (2011) Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int 22:391-420
40. Meier C, Seibel MJ, Kraenzlin ME (2009) Use of Bone Turnover Markers in the Real World: Are We There Yet? J Bone Miner Res 24:386-388
41. Adami S, Isaia G, Luisetto G et al (2006) Fracture incidence and characterization in patients on osteoporosis treatment: the ICARO study. J Bone Miner Res 21:1565-1570 (Pubitemid 44484601)
42. Díez-Pérez A, Olmos JM, Nogués X et al (2012) Risk factors for prediction of inadequate response to antiresorptives. J Bone Miner Res 27:817-824
43. Jobke B, Muche B, Burghardt AJ, Semler J, Link TM, Majumdar S (2011) Teriparatide in bisphosphonate-resistant osteoporosis: microarchitectural changes and clinical results after 6 and 18 months. Calcif Tissue Int 89:130-139
44. Keaveny TM, McClung MR, Wan X, Kopperdahl DL, Mitlak BH, Krohn K (2012) Femoral strength in osteoporotic women treated with teriparatide or alendronate. Bone 50:165-170
45. Hadji P, Gamerdinger D, Spieler W et al (2012) Rapid Onset and Sustained Efficacy (ROSE) study: results of a randomised, multicentre trial comparing the effect of zoledronic acid or alendronate on bone metabolism in postmenopausal women with low bone mass. Osteoporos Int 23:625-633
46. Saag K, Lindsay R, Kriegman A, Beamer E, Zhou W (2007) A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density. Bone 40:1238-1243 (Pubitemid 46550991)
47. Freemantle N, Satram-Hoang S, Tang ET et al (2012) Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women. Osteoporos Int 23:317-326